Clinical Trials on Bone Marrow Neoplasm in Hungary

Total 1672 results

AOP Orphan Pharmaceuticals AG
PharmaEssentia Corporation (Co-Sponsor for USA)

Completed

Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients (PEN-PV)

Polycythemia Vera

Austria, Bulgaria, Czech Republic, France, Hungary, Poland, Slovakia, Ukraine
Kartos Therapeutics, Inc.

Unknown

KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

Polycythemia Vera

United States, Poland, Spain, Germany, Hungary, France
AOP Orphan Pharmaceuticals AG
PharmaEssentia Corporation (for the U.S.)

Completed

AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. (CONTI-PV)

Polycythemia Vera

Spain, Austria, Bulgaria, France, Germany, Hungary, Poland, Romania, Russian Federation, Slovakia, Ukraine, Czechia
AOP Orphan Pharmaceuticals AG
PharmaEssentia (Co-Sponsor for USA)

Completed

Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera (PROUD-PV)

Polycythemia Vera

Spain, Belgium, Austria, Italy, Bulgaria, Czech Republic, France, Germany, Hungary, Poland, Romania, Russian Federation, Slovakia, Ukraine
Novartis Pharmaceuticals

Completed

Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. (RESPONSE-2)

Polycythemia Vera

Hungary, Italy, Belgium, Germany, Spain, Korea, Republic of, Israel, Canada, Turkey, France, Australia, India
Terumo BCT

Completed

Retrospective Data Collection of Routine Use With Spectra Optia® for Platelet Depletions (PLTD)

Thrombocytosis | Thrombocythemia | Myeloproliferative Disease

Denmark, Hungary
Ionis Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

Phlebotomy Dependent Polycythemia Vera

United States, Canada, Hungary, United Kingdom, Australia, Poland
Pfizer

Completed

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Chronic Myeloid Leukaemia

Hungary
Incyte Corporation
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Polycythemia Vera

United States, Canada, France, Italy, United Kingdom, China, Belgium, Germany, Spain, Turkey, Japan, Australia, Korea, Republic of, Netherlands, Russian Federation, Argentina, Thailand, Hungary
Protagonist Therapeutics, Inc.

Recruiting

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (VERIFY)

Polycythemia Vera

United States, Hong Kong, Israel, Canada, Spain, Australia, Austria, Germany, United Kingdom, Hungary, Netherlands, Czechia, Portugal, Italy, Poland, France, Belgium, Chile, Turkey, Mexico
Hoffmann-La Roche

Completed

A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer

Pain; Bone Neoplasms; Neoplasm Metastasis

Hungary
Celgene

Recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

Primary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis

France, Belgium, Spain, Australia, Canada, United States, Korea, Republic of, Romania, Japan, Israel, Italy, Austria, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Argentina, Chile, Colombia and more
Pfizer
Eli Lilly and Company

Completed

Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy

Cancer Pain | Bone Metastasis

China, Spain, Korea, Republic of, Australia, Israel, Japan, Poland, Slovakia, Romania, Austria, Hungary, United Kingdom, Argentina, Brazil, Chile, Czechia
Novartis Pharmaceuticals

Terminated

A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants (STIMULUS-MDS3)

Myelodysplastic Syndrome (MDS)

France, Spain, Belgium, Italy, Greece, Hungary, Germany
Semmelweis University
Purgo Biologics Inc.; FORM-Lab

Completed

Evaluation of a Novel Horizontal Ridge Augmentation Technique in Dentistry

Bone Augmentation | Bone Loss, Alveolar

Hungary
Sanofi

Completed

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis (JAKARTA)

Hematopoietic Neoplasm

Austria, Germany, Italy, Spain, United Kingdom, France, Belgium, Israel, Sweden, Australia, United States, Lithuania, Portugal, Korea, Republic of, Singapore, Taiwan, Mexico, Brazil, Canada, Hungary, Ireland, Poland, Romania, Russian... and more
Scil Technology GmbH
FGK Clinical Research GmbH

Unknown

Pilot Study on MD05 in Comparison With Open Flap Debridement in Patients Undergoing Periodontal Surgery

Periodontal Bone Loss | Alveolar Bone Loss

Hungary
Semmelweis University
NSK Europe GmbH; Hungarian Dental Association

Recruiting

Modified Ridge Splitting Technique Using Autogenous Bone Blocks (MRS) (MRS)

Alveolar Bone Resorption | Alveolar Ridge Enlargement

Hungary
CTI BioPharma

Completed

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post- Essential Thrombocythemia Myelofibrosis

United States, Spain, United Kingdom, Hungary, Korea, Republic of, France, Italy, Sweden
medac GmbH

Completed

Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Germany, Italy, Poland, France, Finland, Hungary
Amgen

Completed

Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer

Bone Metastases in Men With Hormone-Refractory Prostate Cancer | Bone Metastases in Subjects With Advanced Breast Cancer

Spain, Czechia, Peru, Russian Federation, Austria, Lithuania, Poland, South Africa, Italy, Ukraine, Israel, Argentina, Belgium, Brazil, France, Hungary, Japan, Latvia, Panama
Semmelweis University

Recruiting

Clinical, Radiographical, Histological Evaluation and Blood Flow Analysis of Alveolar Ridge Preservation

Alveolar Bone Loss

Hungary
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Novartis Pharmaceuticals

Completed

Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload

Myelodysplastic Syndromes | Beta-Thalassemia

Hungary
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

Myelofibrosis

Italy, Spain, United States, Australia, France, Germany, Greece, Hungary, Israel, Korea, Republic of, Poland, Romania
Semmelweis University
NSK Europe GmbH

Enrolling by invitation

The Introduction of a Novel PAOO Technique

Bone Loss | Tooth Movement

Hungary
Celgene

Completed

An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

Italy, United Kingdom, Germany, Australia, Bulgaria, France, Greece, Hungary, Netherlands, Poland, Spain
Semmelweis University

Completed

Microarchitecture of the Augmented Bone Following Sinus Elevation (MAB)

Alveolar Bone Loss | Edentulous; Alveolar Process, Atrophy | Sinus Pneumatization

Hungary
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Russian Federation, United Kingdom
Urban Regeneration Institute
Szeged University

Completed

Effectiveness of Different Membrane Applications in Vertical Ridge Augmentation

Dental Implants | Bone Regeneration | Polytetrafluoroethylene

Hungary
Hoffmann-La Roche

Terminated

A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain

Pain | Neoplasm Metastasis | Bone Neoplasm

United States, Italy, Chile, Russian Federation, Hungary, United Kingdom, Poland, Guatemala, Germany, Mexico, Puerto Rico, Greece, Australia, Switzerland, Argentina, Panama
European Society for Blood and Marrow Transplantation
Novartis

Completed

Effect of 2nd Gen TKI in CML

Myeloid Leukemia, Chronic

Germany, Finland, Denmark, Poland, Saudi Arabia, United Kingdom, Israel, Hungary, Russian Federation
University of Pecs

Recruiting

Reliability of Clinical Limb-length Measurements Methods

Leg Length Inequality

Hungary
Novartis Pharmaceuticals

Active, not recruiting

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (ADORE)

Myelofibrosis

United Kingdom, Australia, Canada, Switzerland, Netherlands, Spain, Germany, Italy, Turkey, Russian Federation, Sweden, Denmark, Hungary
Semmelweis University

Recruiting

Decompression of Odontogenic Cysts Using an Appliance Fabricated With a Fully Digital Workflow

Odontogenic Cysts

Hungary
CTI BioPharma
PSI CRO

Recruiting

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Spain, Canada, Czechia, United States, Australia, France, Hungary, United Kingdom, Romania, Belarus, Bulgaria, Georgia, Germany, Israel, Italy, Poland, Russian Federation, Serbia, Ukraine, Bosnia and Herzegovina and more
Constellation Pharmaceuticals

Active, not recruiting

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (MANIFEST-2)

Primary Myelofibrosis | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Spain, United States, Canada, Taiwan, Czechia, United Kingdom, Australia, Italy, Belgium, Germany, France, Israel, Greece, Malaysia, Netherlands, Austria, Turkey, Poland, Thailand, Hong Kong, Hungary
Teva Branded Pharmaceutical Products R&D, Inc.
Cephalon; ChemGenex Pharmaceuticals

Completed

Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML

Chronic Myeloid Leukemia

United States, Canada, France, Germany, Hungary, India, Italy, Poland, Singapore, United Kingdom
Incyte Corporation

Active, not recruiting

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, Belgium, France, Israel, China, Japan, Italy, Germany, Taiwan, Poland, Austria, Finland, Hungary, Norway, Romania, Turkey
Sierra Oncology, Inc.

Completed

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis (Simplify 1)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, France, Germany, Spain, Israel, Bulgaria, Romania, Japan, Taiwan, Korea, Republic of, Australia, Belgium, Canada, Netherlands, Singapore, Poland, Hungary, Denmark, Sweden, United Kingdom, Czechia, Austria
Ambrx, Inc.
Merck Serono International SA

Completed

Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).

Growth Hormone Deficiency

Hungary
Hoffmann-La Roche

Terminated

A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease

Pain | Neoplasm Metastasis | Bone Neoplasm

United States, Mexico, Germany, Russian Federation, Italy, Hungary, Belgium, Chile, France, Argentina, Australia, Switzerland, Guatemala, Puerto Rico, Poland, Panama, United Kingdom, Canada
Hanmi Pharmaceutical Company Limited

Completed

Safety and Efficacy Study of Recombinant Human Growth Hormone in Adult Growth Hormone Deficiency Patients (HM10560A)

Adult Growth Hormone Deficiency

Hungary
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia (PAC326)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada, France, United Kingdom, Australia, Belgium, Germany, New Zealand, Netherlands, Russian Federation, Hungary, Czechia
Collagen Solutions

Completed

Follow-Up Study Evaluating the Long Term Outcome of ChondroMimetic in the Treatment of Osteochondral Defects in the Knee

Osteochondral Defect

Hungary
Teva Branded Pharmaceutical Products R&D, Inc.
Cephalon; ChemGenex Pharmaceuticals

Completed

Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

Chronic Myeloid Leukemia

United States, Canada, France, Germany, Hungary, India, Italy, Poland, Singapore, United Kingdom
Sierra Oncology LLC - a GSK company

Completed

A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Canada, Hungary, Israel, Spain, United States, Australia, Taiwan, Singapore, Germany, Italy, France, Belgium, New Zealand, Austria, United Kingdom, Denmark, Bulgaria, Poland, Czechia, Romania, Sweden
Isofol Medical AB

Completed

Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.

Osteosarcoma

Poland, Czechia, Hungary, Sweden
BioCryst Pharmaceuticals

Terminated

BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy (REDEEM-1)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Hungary, France, Italy, Spain
AbbVie

Active, not recruiting

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis (REFINE)

Myelofibrosis (MF)

United States, Australia, Canada, Croatia, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Puerto Rico, Spain, United Kingdom, Taiwan

Clinical Trials on Bone Marrow Neoplasm in Hungary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations